ENOVIS CORP (ENOV) Stock Fundamental Analysis

NYSE:ENOV • US1940141062

23.005 USD
+0.58 (+2.61%)
Last: Feb 24, 2026, 11:02 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

ENOV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. While ENOV is still in line with the averages on profitability rating, there are concerns on its financial health. ENOV scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • ENOV had positive earnings in the past year.
  • ENOV had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: ENOV reported negative net income in multiple years.
  • Of the past 5 years ENOV 4 years had a positive operating cash flow.
ENOV Yearly Net Income VS EBIT VS OCF VS FCFENOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M

1.2 Ratios

  • ENOV has a Return On Assets (-30.84%) which is in line with its industry peers.
  • ENOV's Return On Equity of -67.66% is in line compared to the rest of the industry. ENOV outperforms 45.41% of its industry peers.
  • With a decent Return On Invested Capital value of 0.12%, ENOV is doing good in the industry, outperforming 64.32% of the companies in the same industry.
Industry RankSector Rank
ROA -30.84%
ROE -67.66%
ROIC 0.12%
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ENOV Yearly ROA, ROE, ROICENOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

  • Looking at the Operating Margin, with a value of 0.25%, ENOV is in the better half of the industry, outperforming 64.32% of the companies in the same industry.
  • ENOV's Operating Margin has declined in the last couple of years.
  • With a Gross Margin value of 57.19%, ENOV perfoms like the industry average, outperforming 57.84% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ENOV has grown nicely.
Industry RankSector Rank
OM 0.25%
PM (TTM) N/A
GM 57.19%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
ENOV Yearly Profit, Operating, Gross MarginsENOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ENOV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, ENOV has more shares outstanding
  • ENOV has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ENOV has a worse debt to assets ratio.
ENOV Yearly Shares OutstandingENOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ENOV Yearly Total Debt VS Total AssetsENOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • ENOV has an Altman-Z score of 0.72. This is a bad value and indicates that ENOV is not financially healthy and even has some risk of bankruptcy.
  • ENOV has a Altman-Z score (0.72) which is in line with its industry peers.
  • The Debt to FCF ratio of ENOV is 59.72, which is on the high side as it means it would take ENOV, 59.72 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 59.72, ENOV is in the better half of the industry, outperforming 67.03% of the companies in the same industry.
  • A Debt/Equity ratio of 0.66 indicates that ENOV is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.66, ENOV is doing worse than 65.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 59.72
Altman-Z 0.72
ROIC/WACC0.01
WACC9.61%
ENOV Yearly LT Debt VS Equity VS FCFENOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

  • A Current Ratio of 2.22 indicates that ENOV has no problem at all paying its short term obligations.
  • ENOV has a Current ratio (2.22) which is in line with its industry peers.
  • A Quick Ratio of 1.16 indicates that ENOV should not have too much problems paying its short term obligations.
  • ENOV has a Quick ratio of 1.16. This is in the lower half of the industry: ENOV underperforms 70.27% of its industry peers.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 1.16
ENOV Yearly Current Assets VS Current LiabilitesENOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 26.14% over the past year.
  • Measured over the past years, ENOV shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -16.18% on average per year.
  • The Revenue has grown by 11.57% in the past year. This is quite good.
  • ENOV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.73% yearly.
EPS 1Y (TTM)26.14%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%2.74%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.65%

3.2 Future

  • Based on estimates for the next years, ENOV will show a very strong growth in Earnings Per Share. The EPS will grow by 23.19% on average per year.
  • Based on estimates for the next years, ENOV will show a quite strong growth in Revenue. The Revenue will grow by 8.87% on average per year.
EPS Next Y14.9%
EPS Next 2Y11.19%
EPS Next 3Y11.64%
EPS Next 5Y23.19%
Revenue Next Year7.32%
Revenue Next 2Y6%
Revenue Next 3Y6.02%
Revenue Next 5Y8.87%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ENOV Yearly Revenue VS EstimatesENOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B
ENOV Yearly EPS VS EstimatesENOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 6.91, the valuation of ENOV can be described as very cheap.
  • Based on the Price/Earnings ratio, ENOV is valued cheaper than 98.38% of the companies in the same industry.
  • ENOV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.64.
  • A Price/Forward Earnings ratio of 6.57 indicates a rather cheap valuation of ENOV.
  • 98.38% of the companies in the same industry are more expensive than ENOV, based on the Price/Forward Earnings ratio.
  • ENOV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.75.
Industry RankSector Rank
PE 6.91
Fwd PE 6.57
ENOV Price Earnings VS Forward Price EarningsENOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 93.51% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ENOV indicates a somewhat cheap valuation: ENOV is cheaper than 71.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 57.79
EV/EBITDA 8.77
ENOV Per share dataENOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • ENOV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.46
PEG (5Y)N/A
EPS Next 2Y11.19%
EPS Next 3Y11.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ENOV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENOVIS CORP

NYSE:ENOV (2/24/2026, 11:02:57 AM)

23.005

+0.58 (+2.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners117.36%
Inst Owner Change0.03%
Ins Owners1.14%
Ins Owner Change0.32%
Market Cap1.32B
Revenue(TTM)2.23B
Net Income(TTM)-1.37B
Analysts84.44
Price Target46.36 (101.52%)
Short Float %15.5%
Short Ratio8.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.55%
Min EPS beat(2)7.76%
Max EPS beat(2)13.35%
EPS beat(4)4
Avg EPS beat(4)8.22%
Min EPS beat(4)4.97%
Max EPS beat(4)13.35%
EPS beat(8)8
Avg EPS beat(8)7.21%
EPS beat(12)12
Avg EPS beat(12)8.15%
EPS beat(16)16
Avg EPS beat(16)8.66%
Revenue beat(2)0
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-0.21%
Max Revenue beat(2)-0.09%
Revenue beat(4)0
Avg Revenue beat(4)-0.8%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.09%
Revenue beat(8)2
Avg Revenue beat(8)-0.81%
Revenue beat(12)4
Avg Revenue beat(12)-0.8%
Revenue beat(16)5
Avg Revenue beat(16)-4.71%
PT rev (1m)0%
PT rev (3m)-9.09%
EPS NQ rev (1m)0.92%
EPS NQ rev (3m)1.06%
EPS NY rev (1m)0.29%
EPS NY rev (3m)2.05%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.04%
Valuation
Industry RankSector Rank
PE 6.91
Fwd PE 6.57
P/S 0.59
P/FCF 57.79
P/OCF 6.06
P/B 0.65
P/tB N/A
EV/EBITDA 8.77
EPS(TTM)3.33
EY14.48%
EPS(NY)3.5
Fwd EY15.21%
FCF(TTM)0.4
FCFY1.73%
OCF(TTM)3.8
OCFY16.5%
SpS39.05
BVpS35.33
TBVpS-8.37
PEG (NY)0.46
PEG (5Y)N/A
Graham Number51.45
Profitability
Industry RankSector Rank
ROA -30.84%
ROE -67.66%
ROCE 0.15%
ROIC 0.12%
ROICexc 0.12%
ROICexgc 0.34%
OM 0.25%
PM (TTM) N/A
GM 57.19%
FCFM 1.02%
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-45.54%
ROICexc growth 3YN/A
ROICexc growth 5Y-43.8%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 59.72
Debt/EBITDA 4.5
Cap/Depr 66.6%
Cap/Sales 8.7%
Interest Coverage 250
Cash Conversion 72.98%
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 1.16
Altman-Z 0.72
F-Score4
WACC9.61%
ROIC/WACC0.01
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.14%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%2.74%
EPS Next Y14.9%
EPS Next 2Y11.19%
EPS Next 3Y11.64%
EPS Next 5Y23.19%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.65%
Revenue Next Year7.32%
Revenue Next 2Y6%
Revenue Next 3Y6.02%
Revenue Next 5Y8.87%
EBIT growth 1Y-35.24%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year76.65%
EBIT Next 3Y28.13%
EBIT Next 5Y28.11%
FCF growth 1Y122.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y609.06%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%

ENOVIS CORP / ENOV FAQ

What is the ChartMill fundamental rating of ENOVIS CORP (ENOV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ENOV.


What is the valuation status of ENOVIS CORP (ENOV) stock?

ChartMill assigns a valuation rating of 8 / 10 to ENOVIS CORP (ENOV). This can be considered as Undervalued.


Can you provide the profitability details for ENOVIS CORP?

ENOVIS CORP (ENOV) has a profitability rating of 4 / 10.


What is the earnings growth outlook for ENOVIS CORP?

The Earnings per Share (EPS) of ENOVIS CORP (ENOV) is expected to grow by 14.9% in the next year.